Dyadic announces expanded licensing agreement to develop and commercialize vaccines and biologics for african continent

Jupiter, fla., april 12, 2023 (globe newswire) -- dyadic international, inc. ("dyadic", "we", "us", "our", or the "company") (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its c1-cell protein expression platform with south africa's rubic one health (“rubic”) to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved african countries.
DYAI Ratings Summary
DYAI Quant Ranking